Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Apixaban, 2.5 mg BID + Placebo	1,528
Overall Study	STARTED	Enoxaparin, 40 mg QD + Placebo	1,529
Overall Study	Received Treatment	Apixaban, 2.5 mg BID + Placebo	1,501
Overall Study	Received Treatment	Enoxaparin, 40 mg QD + Placebo	1,508
Overall Study	Evaluable Participants	Apixaban, 2.5 mg BID + Placebo	907
Overall Study	Evaluable Participants	Enoxaparin, 40 mg QD + Placebo	921
Overall Study	Primary Participants	Apixaban, 2.5 mg BID + Placebo	976
Overall Study	Primary Participants	Enoxaparin, 40 mg QD + Placebo	997
Overall Study	COMPLETED	Apixaban, 2.5 mg BID + Placebo	1,392
Overall Study	COMPLETED	Enoxaparin, 40 mg QD + Placebo	1,393
Overall Study	NOT COMPLETED	Apixaban, 2.5 mg BID + Placebo	136
Overall Study	NOT COMPLETED	Enoxaparin, 40 mg QD + Placebo	136

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00452530/flow